JP2010540453A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540453A5
JP2010540453A5 JP2010526011A JP2010526011A JP2010540453A5 JP 2010540453 A5 JP2010540453 A5 JP 2010540453A5 JP 2010526011 A JP2010526011 A JP 2010526011A JP 2010526011 A JP2010526011 A JP 2010526011A JP 2010540453 A5 JP2010540453 A5 JP 2010540453A5
Authority
JP
Japan
Prior art keywords
composition
antibody
targeting moiety
interferon
linker comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010526011A
Other languages
English (en)
Japanese (ja)
Other versions
JP5591701B2 (ja
JP2010540453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/077074 external-priority patent/WO2009039409A1/en
Publication of JP2010540453A publication Critical patent/JP2010540453A/ja
Publication of JP2010540453A5 publication Critical patent/JP2010540453A5/ja
Application granted granted Critical
Publication of JP5591701B2 publication Critical patent/JP5591701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010526011A 2007-09-21 2008-09-19 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン Active JP5591701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99471707P 2007-09-21 2007-09-21
US60/994,717 2007-09-21
PCT/US2008/077074 WO2009039409A1 (en) 2007-09-21 2008-09-19 Targeted interferon demonstrates potent apoptotic and anti-tumor activities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014154820A Division JP6087871B2 (ja) 2007-09-21 2014-07-30 ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す

Publications (3)

Publication Number Publication Date
JP2010540453A JP2010540453A (ja) 2010-12-24
JP2010540453A5 true JP2010540453A5 (enExample) 2011-11-10
JP5591701B2 JP5591701B2 (ja) 2014-09-17

Family

ID=40468388

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010526011A Active JP5591701B2 (ja) 2007-09-21 2008-09-19 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
JP2014154820A Expired - Fee Related JP6087871B2 (ja) 2007-09-21 2014-07-30 ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す
JP2016215048A Pending JP2017031215A (ja) 2007-09-21 2016-11-02 ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014154820A Expired - Fee Related JP6087871B2 (ja) 2007-09-21 2014-07-30 ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す
JP2016215048A Pending JP2017031215A (ja) 2007-09-21 2016-11-02 ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す

Country Status (12)

Country Link
US (5) US9139634B2 (enExample)
EP (3) EP3150218B1 (enExample)
JP (3) JP5591701B2 (enExample)
KR (2) KR101759460B1 (enExample)
CN (3) CN103880965B (enExample)
AU (1) AU2008302111B2 (enExample)
BR (1) BRPI0817108B8 (enExample)
CA (1) CA2699944C (enExample)
ES (1) ES2536772T3 (enExample)
IL (2) IL204644A (enExample)
MX (2) MX349306B (enExample)
WO (1) WO2009039409A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
EP3150218B1 (en) * 2007-09-21 2021-09-08 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
WO2011068993A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
CA2802857C (en) * 2010-06-16 2018-09-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
CA2902942C (en) 2010-07-28 2020-12-22 David S. Block Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
US8883982B2 (en) * 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US8961971B2 (en) 2011-12-22 2015-02-24 Development Center For Biotechnology Bispecific T-cell activator antibody
US9492562B2 (en) 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
NZ714549A (en) 2012-04-30 2016-10-28 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
RU2015109591A (ru) * 2012-08-20 2016-10-20 Гликник Инк. Молекулы с антигенсвязывающей активностью и способностью к поливалентному связыванию с fc-гамма-рецепторами
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
AU2014249405C1 (en) 2013-03-12 2018-08-16 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
WO2015006736A2 (en) 2013-07-11 2015-01-15 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof
WO2015007536A2 (en) 2013-07-18 2015-01-22 Vib Vzw Fusokines involving cytokines with strongly reduced receptor binding affinities
EP3021865B1 (en) 2013-07-19 2018-06-13 Vib Vzw Targeted modified tnf family members
US9932409B2 (en) 2013-07-19 2018-04-03 Vib Vzw Targeted modified IL-1 family members
WO2015007520A1 (en) 2013-07-19 2015-01-22 Vib Vzw Targeting of cytokine antagonists
EP3030268B1 (en) * 2013-08-09 2022-07-27 The Trustees Of The University Of Pennsylvania Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
WO2015057834A1 (en) * 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
EP3078744B1 (en) 2013-12-04 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
US10501553B2 (en) * 2014-11-19 2019-12-10 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of EphA2
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US20170002057A1 (en) * 2015-02-26 2017-01-05 Nal Pharmaceutical Group Limited Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same
US20210009720A1 (en) * 2015-03-03 2021-01-14 Genopharm Inc. Human interferon-beta variant conjugated immunocytokine and method for preparing same
KR101838919B1 (ko) * 2015-03-03 2018-03-15 에이비온 주식회사 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3307301A4 (en) * 2015-06-12 2019-04-10 ImmunGene, Inc. FOCUSED INTERFERON IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
JP6452577B2 (ja) * 2015-08-27 2019-01-16 株式会社沖データ 画像形成装置
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US10919950B2 (en) 2016-01-14 2021-02-16 Seattle Children's Hospital Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
EP4276114A3 (en) 2016-03-07 2024-02-21 Vib Vzw Cd20 binding single domain antibodies
WO2017180764A1 (en) * 2016-04-12 2017-10-19 Immungene, Inc. Focused interferon immunotherapy
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
CN110087673A (zh) 2016-07-19 2019-08-02 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
ES3030503T3 (en) 2016-10-19 2025-06-30 Scripps Research Inst Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
JP7128529B2 (ja) * 2016-12-23 2022-08-31 アールイーエムディー バイオセラピューティクス，インコーポレイテッド プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
KR102659140B1 (ko) 2017-08-09 2024-04-19 오리오니스 바이오사이언시스 인코포레이티드 Clec9a 결합제 및 그의 용도
CN111328286B (zh) 2017-08-09 2024-08-23 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
CA3069930A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Cd8 binding agents
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
WO2019182996A1 (en) * 2018-03-19 2019-09-26 The Regents Of The University Of California Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
US10858412B2 (en) * 2019-03-06 2020-12-08 Deka Biosciences, Inc. Antibody variable domain regions fused to IL-10 variant molecules
US11440943B2 (en) 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
EP3947429A4 (en) 2019-03-28 2023-05-17 Orionis Biosciences, Inc. CLEC9A-BASED CHIMERA PROTEIN COMPLEXES
KR20210153092A (ko) 2019-04-15 2021-12-16 퀴셀 세라퓨틱스 엘엘씨 암 치료에 사용하기 위한, 마스킹된 유형 i 인터페론(ifna 및 ifnb) 및 종양 항원에 대한 항체를 포함하는 융합 단백질 조성물
KR20210021861A (ko) * 2019-08-19 2021-03-02 (주)제노팜 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
CA3155981A1 (en) * 2019-11-14 2021-05-20 William Winston Activatable cytokine polypeptides and methods of use thereof
JP2023505168A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インターフェロン会合抗原結合タンパク質及びこれらの使用
WO2021222228A1 (en) * 2020-04-27 2021-11-04 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
MX2023000948A (es) 2020-07-20 2023-04-14 Deka Biosciences Inc Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).
JP7649923B2 (ja) * 2021-08-12 2025-03-21 上▲海▼津曼特生物科技有限公司 ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用
KR20240015037A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 Vc1 분비를 위한 재조합 발현 벡터 및 이로 형질전환된약독화 살모넬라 균주
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
US20240376229A1 (en) 2023-05-12 2024-11-14 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
WO2025106883A1 (en) * 2023-11-15 2025-05-22 President And Fellows Of Harvard College Engineered fc-prolactin fusions to increase lactation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
JP3854306B2 (ja) 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
ES2191702T3 (es) 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
DK0706799T3 (da) 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
WO1997013529A1 (en) 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
SK282326B6 (sk) * 1996-02-20 2002-01-07 Applied Research Systems Ars Holding N. V. Hybridný proteín tvoriaci heterodimér, molekula DNA, expresný vektor, hostiteľská bunka, spôsob produkcie hybridného proteínu a farmaceutická zmes
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
ATE269100T1 (de) * 1998-10-05 2004-07-15 Pharmexa As Verfahren zur therapeutischen impfung
MXPA01003790A (es) * 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
ES2317843T3 (es) * 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. Proteinas de fusion de eritropoyetina-inmunoglobulina.
EP1276856A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2001097844A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
PT1355942E (pt) 2000-12-07 2008-11-21 Lilly Co Eli Proteínas de fusão de glp-1
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1519959B1 (en) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20070003514A1 (en) 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
CA2516293A1 (en) * 2003-02-18 2004-09-02 Tim Jones Fusion proteins of interferon alpha muteins with improved properties
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR100863776B1 (ko) * 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체
US20090221477A1 (en) * 2004-07-26 2009-09-03 Asterion Limited Linkers
AU2006203850A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CN101484182B (zh) * 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
CN101184771A (zh) * 2005-05-26 2008-05-21 先灵公司 干扰素－IgG融合体
AU2006263331B2 (en) * 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP3150218B1 (en) * 2007-09-21 2021-09-08 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20100047164A1 (en) 2008-04-11 2010-02-25 Duke University Anti-Tumor Antibodies
WO2009134870A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
JP2012503203A (ja) 2008-09-19 2012-02-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体
WO2010128087A2 (en) 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy
US9296811B2 (en) 2010-12-02 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds HMW-MAA
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
AU2011378675B2 (en) 2011-10-04 2017-10-05 Epsilogen Ltd IgE anti -HMW-MAA antibody
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy

Similar Documents

Publication Publication Date Title
JP2010540453A5 (enExample)
JP2010516290A5 (enExample)
JP2010516708A5 (enExample)
RU2012129208A (ru) Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
CN105142663A (zh) 用于癌症靶向治疗的含有结合白蛋白的精氨酸脱亚胺酶的药物组合物
JP2009539367A5 (enExample)
JP2009507470A5 (enExample)
CN110981958B (zh) 一种pd-l1抗体
JP2013513377A5 (enExample)
JP2022509017A (ja) 抗ｐｔｋ７免疫細胞癌療法
JP2018512124A5 (enExample)
JP2010509931A5 (enExample)
JP7330517B2 (ja) 異種タンパク質産生のための人工分泌ペプチド
JP2009540852A5 (enExample)
CN110300766A (zh) 新型重组双功能融合蛋白及其制备方法和用途
CN105111314A (zh) 一种新型融合蛋白、药物组合物及其制备方法和用途
WO2023020537A1 (zh) 一种双特异性抗体及其用途
CN111218443B (zh) 合成核酸药物偶联物的方法
CN101143902B (zh) 抗HER2单链抗体-力达霉素强化融合蛋白HER2(Fv-LDM)
JP2006345867A5 (enExample)
CN108341854A (zh) 一种肿瘤靶向的新型多肽及其用途
JP7239987B2 (ja) 薬物送達のための抗体融合タンパク質
CN117964760B (zh) 抗人cll1/cd3的双特异性抗体及其应用
JP2015533372A5 (enExample)
CN101210048A (zh) 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途